DIEPENBEEK, Belgium, February 4, 2014 /PRNewswire/ --
Amakem Therapeutics, a clinical stage ophthalmology company, today announced that it will participate in the Glaucoma 360 New Horizons Forum being held on Friday, February 7, 2014 at The Palace Hotel, in San Francisco. This meeting, presented by Glaucoma Research Foundation, brings together key clinical, industry, financial and regulatory leaders in a unique exchange on research innovation and advances in glaucoma treatment. Globally, glaucoma is a leading cause of preventable blindness.
Dr. Jack Elands, CEO of Amakem, will present an update on the Company's lead candidate, AMA0076, a highly potent locally-acting Rho Kinase (ROCK) inhibitor under development for the treatment of glaucoma. In top line clinical results presented in November 2013, AMA0076 demonstrated IOP reduction without significant hyperemia, the first ROCK inhibitor to achieve this goal in the clinic.
Thomas M. Brunner, President and CEO of Glaucoma Research Foundation, said, "This unique full-day meeting unites medicine, research, and industry with one mission - to find a cure for glaucoma."
Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew Iwach, MD, both of whom serve on the Glaucoma Research Foundation Board of Directors. Drs. Graves and Iwach also serve as Co-Chairs for the Glaucoma 360 New Horizons Forum. Dr. Iwach, GRF Board Chair and Executive Director at the Glaucoma Center of San Francisco, said, "Glaucoma 360 is designed to bring greater awareness to unmet medical needs in glaucoma and to highlight current and novel therapies that will help preserve sight for glaucoma patients."
About Glaucoma Research Foundation
Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $40 million to advance essential research and education programs. More information is available at http://www.glaucoma.org/about.
Amakem Therapeutics is an ophthalmology company developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective kinase inhibitors that minimize side effects.
Amakem's lead candidate, AMA0076, is in clinical development for IOP reduction in patients with glaucoma or ocular hypertension. The Company is also working to apply the Localized Drug Action approach to a range of other eye diseases.
Founded in 2010, Amakem has raised more than €21m in funding and is backed by leading life sciences investors including Forbion, Omnes Capital (previously Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science Research Partners.
Amakem is based in Belgium and located in the life sciences incubator "BioVille" at the University of Hasselt.
For more information, please contact
Jack Elands, CEO
Citigate Dewe Rogerson
SOURCE Amakem Therapeutics